Afb Mtb - Isoniazid Antibiogram Infected Tissue

Drug susceptibility testing should be performed on the organisms initially isolated from all patients with newly diagnosed tuberculosis. If the bacilli becomes resistant, therapy must be changed to agents to which the bacilli are susceptible. Used in both the treatment and prophylaxis of tuberculosis; neurologic side-effects can occur, but these can be prevented with pyridoxine. Patients should be monitored for liver toxicity. Treatment and prophylaxis doses are 300 mg a day. o determine the characteristics of pulmonary tuberculosis (TB) patients harbored organisms with isoniazid mono-resistant drug susceptibility pattern. Therefore, patients given isoniazid should be carefully monitored and interviewed at monthly intervals. Isoniazid is used in conjunction with other effective anti-tuberculous agents. Ethambutol or streptomycin should be added to the initial regimen until sensitivity to isoniazid and rifampin is demonstrated. The addition of a fourth drug is optional if the relative prevalence of isoniazid-resistant Mycobacterium tuberculosis isolates in the community is less than or equal to four percent.